Based on these findings, future therapeutics could target LOX-mediated collagen crosslinking to enhance mechanical properties of abnormally weak tendons during treatment of connective tissue disorders and musculoskeletal abnormalities in childhood years. The gene discussed is LOX; the disease is connective tissue disorder.